⌕
Tempus AI · TEM · Nasdaq
Tenet 34 · Weak
Compare
$64.76−9.55%At closeTenet 34 · Weak
$64.76−6.84 (−9.55%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Tempus AI (TEM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Newsfile CorpNov 12, 2026 · 05:00 ET
Arizona Eagle Mining Corp. Announces Completion of High Resolution TEM Geophysical Survey at the Eagle Project and Provides Update on McCabe Mine Reopening Studies

Toronto, Ontario--(Newsfile Corp. - November 12, 2026) - Arizona Eagle Mining Corp. (TSXV: AZEM) (OTCQB: AZEMF) (the "Company" or "Arizona Eagle") is pleased to announce the completion of a 708 line-kilometre airborne ti…

● Business WireNov 11, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting takin…

● PRNewsWireNov 9, 2026 · 16:39 ET
SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer

SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation , a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatme…

● Seeking AlphaNov 7, 2026 · 21:48 ETEARNINGS EXPECTED BY FEB 24
Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up

Tempus is rated 'hold' as current valuation already prices in considerable future success. The platform's core strength lies in connecting diagnostic data with clinical outcomes, enhancing research value and recurring re…

● Seeking AlphaNov 4, 2026 · 05:49 ETEARNINGS EXPECTED BY FEB 24
Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)

Tempus AI delivered robust Q3 results, with 23% YoY revenue growth and an inflection after four quarters of deceleration. Diagnostics volumes surged, notably MRD tests up 300% YoY, while Data & Applications revenue accel…

● MarketBeatNov 3, 2026 · 11:35 ETEARNINGS EXPECTED BY FEB 24
Tempus AI Surges on Earnings Beat, But Can the Rally Last?

Tempus AI NASDAQ: TEM is among the more volatile AI-related stocks, trading in a wide range and testing upper limits several times since its IPO. Volatility stems from several factors, including the path to profitability…

● Zacks Investment ResearchNov 3, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 24
TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside

Tempus AI raises its 2026 revenue outlook as oncology demand, expanding data partnerships and reimbursement-driven pricing gains fuel growth prospects for 2027.…

● Seeking AlphaNov 3, 2026 · 08:10 ETEARNINGS EXPECTED BY FEB 24
Baron SMID Cap ETF Q3 2026 Contributors And Detractors

Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming its benchmark, the Russell 2500 Growth Index, which returned -10.35%. Top contributors were Rubrik, Inc., Tempus AI, Inc., and Netskope, Inc. T…

● BenzingaNov 3, 2026 · 07:02 ETEARNINGS EXPECTED BY FEB 24
Tempus AI Analysts Boost Their Forecasts Following Strong Q3 Results

Tempus AI Inc. (NASDAQ:TEM) on Monday posted upbeat results for the third quarter.…

● 24/7 Wall StreetNov 2, 2026 · 14:54 ETEARNINGS EXPECTED BY FEB 24
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge

Tempus AI (NASDAQ:TEM | TEM Price Prediction) was trading higher this afternoon. It sat at $80.31, up 11.21% after the precision medicine company reported third-quarter results before the open.…

● Seeking AlphaNov 2, 2026 · 13:28 ETEARNINGS EXPECTED BY FEB 24
Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript

Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript…

● BenzingaNov 2, 2026 · 12:37 ETEARNINGS EXPECTED BY FEB 24
Tempus AI Says It Is Uniquely Positioned

Tempus AI Inc. (NASDAQ:TEM) shares were trading higher on Monday after the company reported third-quarter adjusted earnings of 7 cents per share, swinging from a loss of 8 cents, beating the consensus per-share loss of 1…

● Zacks Investment ResearchNov 2, 2026 · 12:31 ETEARNINGS EXPECTED BY FEB 24
Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago…

● Zacks Investment ResearchNov 2, 2026 · 12:20 ETEARNINGS EXPECTED BY FEB 24
Tempus AI (TEM) Beats Q3 Earnings and Revenue Estimates

Tempus AI (TEM) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.11 per share a year ago.…

● MarketBeatNov 2, 2026 · 11:14 ETEARNINGS EXPECTED BY FEB 24
What Tempus AI (TEM) Said on Its Q3 Earnings Call

Tempus AI NASDAQ: TEM reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive results. The company also r…

● The Motley FoolNov 2, 2026 · 11:09 ETEARNINGS EXPECTED BY FEB 24
Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reaction

Data and Applications revenue grew 33% and earns gross margins above 71%, so its faster growth lifts company-wide margins. The adjusted EBITDA outlook held at about $65 million, implying a jump to roughly $34 million in …

● BarronsNov 2, 2026 · 08:11 ETEARNINGS EXPECTED BY FEB 24
Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer

Tempus AI reported better-than-expected third-quarter earnings.…

● Business WireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 24
Tempus Reports Third Quarter 2026 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026. “Q3 was a…

● Defense WorldNov 2, 2026 · 05:59 ET
Head-To-Head Contrast: Tempus AI (NASDAQ:TEM) versus P3 Health Partners (NASDAQ:PIII)

P3 Health Partners (NASDAQ: PIII - Get Free Report) and Tempus AI (NASDAQ: TEM - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the streng…

● Defense WorldOct 31, 2026 · 04:09 ET
Tempus AI (NASDAQ:TEM) Stock: Insider Eric Lefkofsky Sells 250,000 Shares

Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $70.36, for a total value of $17,…

● Zacks Investment ResearchOct 30, 2026 · 11:16 ETEARNINGS EXPECTED BY FEB 24
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?

Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.…

● 24/7 Wall StreetOct 27, 2026 · 09:28 ETEARNINGS EXPECTED BY FEB 24
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings

Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the past month.…

● Zacks Investment ResearchOct 26, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 24
Tempus AI (TEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Business WireOct 26, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic devic…

● Business WireOct 23, 2026 · 09:00 ET
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) an…

● Business WireOct 23, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Tempus Expands Strategic Collaboration with Bristol Myers Squibb

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus thr…

● Business WireOct 19, 2026 · 08:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 24
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC). The panel achieved …

● Business WireOct 15, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 24
Tempus to Report Third Quarter 2026 Financial Results on November 2

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended Septemb…

Business Wire · Nov 2, 2026

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 24. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just TEM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.